Novel Drugs in a Pipeline for Progressive Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is an inflammatory, demyelinating central nervous system disease.
• Progressive multiple sclerosis (PMS) pathogenesis involves complex, multi-level processes, shifting from inflammation to neurodegeneration over time.
• Current anti-inflammatory treatments for PMS show limited long-term efficacy.

Purpose of the Study:

• To review compounds with potential neuroprotective or remyelinating effects for progressive multiple sclerosis (PMS).
• To assess drugs that have advanced to the clinical trial phase for PMS treatment.
• To discuss future therapeutic strategies for progressive multiple sclerosis.

Main Methods:

• Literature review of clinical studies on drugs for progressive multiple sclerosis (PMS).
• Inclusion of compounds that have entered the clinical assessment phase.
• Analysis of pathogenetic mechanisms and therapeutic challenges in PMS.

Main Results:

• Identified several drug candidates including biotin, ibudilast, simvastatin, alpha-lipoic acid, clemastine, amiloride, fluoxetine, riluzole, masitinib, opicinumab, and lamotrigine.
• Highlighted the transition from inflammatory to neurodegenerative processes in PMS pathogenesis.
• Acknowledged the limited efficacy of current anti-inflammatory therapies in later disease stages.

Conclusions:

• Novel therapeutic approaches targeting neuroprotection and remyelination are crucial for effective progressive multiple sclerosis (PMS) treatment.
• Further clinical evaluation of identified compounds is necessary to establish their role in PMS therapy.
• Understanding the evolving pathogenetic mechanisms is key to developing successful long-term treatments for PMS.